[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopausal-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopausal-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,68,94,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100639704","algal-lutein-against-decline-of-intellectual-nimbleness-100639704",false,"NCT07600567","Algal Lutein Against Decline of Intellectual Nimbleness","ALADIN","Inclusion Criteria:\n\n* Females\n* Age 48-60 years\n* Postmenopausal status (natural menopause, up to 5 years after menopause)\n* waist circumference ≥ 88 cm\n\nExclusion Criteria:\n\n* Diagnosis of dementia or cognitive impairment\n* Use of hormone replacement therapy within the last 6 months\n* Advanced age-related macular degeneration\n* History of major untreated neurological or psychiatric disorders (including depression, Parkinson's disease, Alzheimer's disease, psychiatric disorders, stroke within the last 3 months)\n* Presence of chronic diseases, including: diabetes mellitus (type 1 or 2), lipid disorders, cardiovascular diseases, thyroid diseases, anemia, liver diseases, gastrointestinal disorders, or cancer within the last 5 years\n* Use of anti-inflammatory medications or medications targeting lipid or carbohydrate metabolism within the last 3 months\n* Alcohol consumption \\> 100 g per week\n* Use of lutein-containing supplements",true,"FEMALE","48 Years","60 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","Lutein is a xanthophyll pigment found in photosynthesizing organisms. Its beneficial effects on health, including brain function and visual performance, have been recognized for many years. However, to date, only a limited number of well-designed human intervention studies have been published regarding the effects of incorporating lutein into the daily diet (as humans are unable to synthesize lutein endogenously). Unfortunately, within the Western dietary pattern, the average daily intake of lutein is approximately 1.7 mg, whereas achieving health benefits- such as reducing the risk of age-related macular degeneration and cataract, as well as neurodegenerative diseases- requires an intake of 6 to 14 mg per day.\n\nIn light of the above, it is therefore justified to enrich the daily diet with products that are sources of lutein. Unfortunately, the consumption of dark green vegetables- the richest dietary source of lutein-remains insufficient. Lutein preparations currently available on the market are extracted from marigold or calendula flowers. However, lutein production from these raw materials requires greater water consumption and land use, which is not aligned with the principles of sustainable development. An alternative approach involves the production of lutein preparations from microalgae (from species approved as food by the European Food Safety Authority, EFSA), as the rate of lutein production from microalgae is three to six times higher than that from marigold flowers.\n\nTaking the above into account, the primary objective of this project is to evaluate the dose-response relationship in establishing the anti-aging mechanism of action of lutein derived from microalgae.\n\nAs part of the project, a six-month randomized, placebo-controlled trial is planned. The study will include 300 polish women (aged 48-60 years), after natural menopause, with visceral obesity (waist circumference ≥ 88 cm). In order to enable the inclusion of such a large study population, the research team will conduct intensified recruitment efforts for several months prior to the initiation of the dietary intervention.\n\nParticipants who meet the inclusion criteria will be randomly assigned to one of three groups: lutein supplementation at a dose of 6 mg (n = 100), lutein supplementation at a dose of 14 mg (n = 100), or placebo (n = 100). The volunteers will be instructed to take the prescribed preparation daily for 180 days. All preparations will be identical in appearance, taste, and smell.\n\nAll volunteers expressing willingness to participate in the experiment will be asked to provide written informed consent prior to enrollment in the study.\n\nThe study will be conducted in accordance with the previously calculated sample size (n = 300 postmenopausal women with visceral obesity). In order to obtain a homogeneous study population, appropriate inclusion and exclusion criteria will be applied.\n\nConducting the research in such a large and homogeneous group will enable the generation of high-quality scientific evidence identifying the dose of microalgae-derived lutein that allows for the determination of its anti-aging mechanism of action. It will also be possible to elucidate the potential role of short-chain fatty acids (SCFAs) in feces in this process, which may represent a significant novelty in this field of research.\n\nThe study will contribute to the development of new knowledge regarding the anti-aging properties of lutein derived from microalgae in populations vulnerable to cognitive impairment (postmenopausal women). However, microalgae-derived lutein may be used as a dietary supplement not only in the studied group but also in the general population.\n\nThe specific objectives are as follows:\n\n* To assess the effect of lutein derived from microalgae (at doses of 6 mg and 14 mg) on the concentration of brain-derived neurotrophic factor (BDNF), inflammatory markers, cardiometabolic parameters, fecal short-chain fatty acid (SCFA) concentrations, and cognitive function in postmenopausal women with visceral obesity.\n* To evaluate adherence to lutein supplementation recommendations (by assessing macular pigment optical density).\n* To determine whether supplementation with microalgal lutein increases fecal SCFA concentrations and whether SCFAs may act as mediators in improving inflammatory markers and cognitive function in postmenopausal women with visceral obesity.\n* To determine whether supplementation with microalgal lutein (at doses of 6 mg and 14 mg) affects changes in selected gut bacterial populations and β-glucuronidase enzymatic activity in postmenopausal women with visceral obesity.\n* To analyse the association between polymorphisms in genes related to lutein metabolism and transport in the body and the effectiveness of supplementation with this compound.\n* To identify dietary behaviour patterns associated with high exposure to bisphenol A (BPA) and the presence of inflammation in postmenopausal women with visceral obesity.",[28,29,30,31,32,33,34,35],"Menopausal Syndrome","Cognitive Decline","Obesity & Overweight","Menopause","Inflamation","Gut Dysbiosis","Bisphenol A","Cardio Vascular Disease",[37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54],"menopausal syndrome","cognitive decline","obesity","menopause","inflammation","dysbiosis","bisphenol A","gut microbiota","BNDF","intellectual nimbleness","beta-glucuronidase","lutein","supplementation","micro-algae","gene polimorfism","eye vision","chlorella","sustainable development","NOT_YET_RECRUITING","2026-05-13",{"date":58,"type":59},"2026-05-20","ACTUAL",{"date":61,"type":22},"2026-05-01",{"date":63,"type":22},"2027-04-30",{"name":65,"class":66},"Poznan University of Life Sciences","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100583316","a-real-world-clinical-study-on-the-treatment-of-menopausal-syndrome-with-liuwei-dihuang-pills-100583316","NCT06874738","A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills","Inclusion Criteria:\n\n1. Age: 45-55 years old\n2. Patients with menopausal syndrome using Liuwei Dihuang Pills\n3. Kidney Yin Deficiency Syndrome\n\nExclusion Criteria:\n\n1. Individuals allergic to any components of the drug or excipients;\n2. Individuals with other endocrine diseases;\n3. Individuals with organic lesions of the reproductive system;\n4. Individuals who have undergone bilateral oophorectomy, hysterectomy, or have ovarian dysfunction;\n5. Individuals with endometrial hyperplasia or unexplained vaginal bleeding;\n6. Individuals with malignant tumors, hematologic, or immune system diseases;\n7. Individuals with severe cardiovascular, cerebrovascular, liver, or kidney diseases (e.g., serum transaminase levels more than 1.5 times the upper limit of normal, serum creatinine above the upper limit of normal);\n8. Individuals with psychiatric disorders or dependence on alcohol or drugs;\n9. Individuals with mental illness or communication barriers;\n10. Individuals with other conditions that, in the investigator's judgment, may reduce the likelihood of enrollment or complicate the study process are not suitable for participation in this clinical research.","45 Years","55 Years",{"count":77,"type":22},1000,"OBSERVATIONAL","To evaluate the clinical efficacy of the real-world Liuwei Dihuang pills for the treatment of female menopausal syndromes, and to provide a basis for effective, safe and rational clinical use of the drug.",[28],[82,83,84,85],"Liuwei Dihuang Pills","The real world","Efficacy","Clinical study","2025-03-08",{"date":88,"type":59},"2025-03-13",{"date":86,"type":22},{"date":91,"type":22},"2026-12-30",{"name":93,"class":66},"China Academy of Chinese Medical Sciences",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":67},"100364916","phase-2-autologous-prp-infusion-may-restore-ovarian-function-and-may-promote-folliculogenesis-in-poi-patients-100364916","NCT04031456","Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients","Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients","PRP","Inclusion Criteria:\n\n* Age \\\u003C 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels \\>25 IU\u002FL recorded on two occasions \\>4 weeks apart\n* Normal Karyotype: 46, XX\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* AMH \\> 8 pmol\u002FL\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders","25 Years","39 Years",{"count":105,"type":22},100,[107,108],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.",[111,112,28,113,114],"Menopause, Premature","Menopause Related Conditions","Premature Ovarian Failure","Ovarian Failure, Premature","RECRUITING","2024-12-20",{"date":118,"type":59},"2024-12-24",{"date":120,"type":59},"2019-07-30",{"date":122,"type":22},"2026-07-30",{"name":124,"class":66},"Genesis Athens Clinic",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":67},"100460776","hrt-on-overactive-bladder-symptoms-sexual-function-depressive-symptoms-autonomic-function-and-arterial-stiffness-100460776","NCT05280028","HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness","The Impact of Different Hormone Therapy Regimens on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness","Inclusion Criteria:\n\n* \\>20 years old female\n* Menopausal symptoms, still have a uterus, and no breast or other cancers, and no vascular-blocking disease such as stroke.\n\nExclusion Criteria:\n\n* Nil.","20 Years",{"count":105,"type":22},"Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V\u002FMPA.\n\nFrom the results, the investigators will compare the effect of tibolone versus E2V\u002FMPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.",[28],"2024-06-13",{"date":138,"type":59},"2024-06-17",{"date":140,"type":59},"2022-02-07",{"date":142,"type":22},"2026-12-31",{"name":144,"class":66},"Far Eastern Memorial Hospital"]